DelveInsight’s Trending Reports 2022: Ehlers-Danlos Syndrome Market, X Linked Hypophosphatemia Market, Thyroid Eye Disease Market, Primoridal Dwarfism Market, Sialidosis Market.
Ehlers-Danlos Syndrome Market
Ehlers-Danlos
syndrome (EDS) is a disease that weakens the connective tissues of your
body. These are things like tendons and ligaments that hold parts of your body
together. EDS can make your joints loose and your skin thin and easily bruised.
It also can weaken blood vessels and organs.
Some facts of Ehlers-Danlos
Syndrome Market Report are:
·
The combined prevalence of all types of
Ehlers-Danlos syndrome appears to be at least 1 in 5,000 individuals
worldwide.
·
Vascular EDS is reported to have a prevalence of
1 in 100,000 individuals, and cardiac-valvular EDS a prevalence of less than 1
in a million people.
·
The estimated prevalence for all EDS varies
between 1/10,000 and 1/25,000, EDS type IV representing approximately 5 to 10%
of cases.
View Report: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market
Some of Ehlers-Danlos
Syndrome Companies are:
·
Aventis Pharmaceuticals
·
EVAMED
·
Acer Pharma
·
And Many Others
View Report: https://www.delveinsight.com/report-store/ehlers-danlos-syndrome-market
Ehlers-Danlos
Syndrome Therapies are:
·
Celiprolol
·
Irbesartan
·
And Many Others
X Linked
Hypophosphatemia Market
X-linked
hypophosphatemia is a hereditary renal phosphate-wasting disorder
characterized by hypophosphatemia, rickets and/or osteomalacia, and diminished
growth. Phosphate levels are low because phosphate is abnormally processed in
the kidneys, which causes a loss of phosphate in the urine (phosphate wasting)
and leads to soft, weak bones (rickets). XLH is usually diagnosed in childhood.
Features include bowed or bent legs, short stature, bone pain, and severe
dental pain. XLH is the most common form of hereditary hypophosphatemic
rickets.
Some facts of X
Linked Hypophosphatemia Market Report are:
·
According to study conducted by He ́le`ne et
al., titled “Impaired quality of life in adults with X-linked hypophosphatemia
and skeletal symptoms”, the estimated prevalence of X-linked hypophosphatemia
was 4.8 per 100,000.
·
As per Endocrine Society, the Food and Drug
Administration (FDA) estimates that XLH affects about 3,000 children and 12,000
adults in the United States
·
According to Phosphodiabetes E.V. Netzwerk
Information Austausch, estimates that X-linked hypophosphatemia (XLH) is the
most common form of vitamin D-resistant rickets and, with a prevalence of 4.8
cases per 100,000 individuals, is considered a rare disease.
·
The study by Riancho et al., titled
“Osteomalacia and rickets” estimates that the prevalence of Hypophosphatemic
rickets linked to the X chromosome due to a mutation in the PHEX gene is around
5 per 100,000.
View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
Some of X
Linked Hypophosphatemia Companies are:
·
Ultragenyx
·
Validus Pharmaceuticals
·
Prospec-Tany Technogene Ltd
·
Merck KGaA
·
Zeria Pharmaceutical Co., Ltd
·
Smith & Nephew
·
Narang Medical Limited
·
Eli Lilly and Company
·
F. Hoffmann-La Roche Ltd
·
And Many Others
View Report: https://www.delveinsight.com/report-store/x-linked-hypophosphatemia-market
X
Linked Hypophosphatemia Therapies are:
·
Burosumab
·
Crysvita
·
And Many Others
Thyroid Eye Disease
Market
Thyroid
eye disease (TED)—also
known as Graves’ Orbitopathy or Ophthalmopathy—is an autoimmune condition. It
occurs when the body’s immune system attacks the tissue surrounding the eye
causing inflammation in the tissues around and behind the eye. It appears that
the same antibody that can cause thyroid dysfunction may also have an
"attraction"to tissuessurrounding the eyes causing the onset of
Graves' Ophthalmopathy. Moreover, the disease is categorized as mild, moderate,
and severe.
Some of Thyroid
eye disease Facts:
·
In a
study by Zagaria et al. [2011], it was observed that approximately 25‐30% of patients
with Graves’ disease have clinical evidence of Graves’ ophthalmopathy.
·
As per
the study by Liaboe et al., titled “An Introductory Tutorial and Overview of
Disease”, TED has a higher prevalence in women than men (16 per 100,000 vs. 3
per 100,000, respectively). Both men and women demonstrate a bimodal pattern of
age of diagnosis(40–44 and 60–64 yearsin women; 45–49 and 65–69 years in men).
·
The
study by Lazarus et al. titled “Epidemiology of Graves’ orbitopathy (GO and
relationship with thyroid disease” estimates that Graves’ ophthalmopathy (GO)
occurs mainly, but not exclusively, in patients with Graves’ disease. However,
only about <50% of Graves’ patients have clinically apparent ophthalmopathy,
where the approximate prevalence is 0.25%.
·
According
to a review article titled “Epidemiology and Prevention of Graves’
Ophthalmopathy” by Wilmar et al., Graves’ ophthalmopathy is clinically relevant
in approximately 50% of patients with Graves' disease, and severe forms affects
less than 5% of patients.
View Report: https://www.delveinsight.com/report-store/thyroid-eye-disease-market
Some of Thyroid
eye disease Companies:
·
Immunovant
Sciences
·
Horizon
Therapeutics
·
And Many
Others
Thyroid
eye disease Drugs Covered:
·
IMVT‐1401
·
Teprotumumab
·
And Many
Others
View Report: https://www.delveinsight.com/report-store/thyroid-eye-disease-market
Primoridal Dwarfism
Market
Primordial dwarfism is a rare and
often dangerous group of genetic conditions that result in a small body size
and other growth abnormalities. Signs of the condition first appear in the
fetal stage and continue through childhood, adolescence, and adulthood.
Some facts of Primordial Dwarfism Market Report:
·
Primordial Dwarfism Market size is expected to
change for 7MM during the forecast period of 2018-30.
·
Its prevalence report estimates 4 million babies
to die in the first 4 weeks of life (the neonatal period) with almost 99 % of
neonatal deaths (Lawn et al. 2011; Cous-ens et al. 1995).
·
The modern prevalence of MOPDII is unknown, but
between 150 and 200 cases are reported worldwide each year (Bober and Jackson,
2017).
·
All types of primordial dwarfism are caused by
changes in genes. Different gene mutations cause the different conditions that
make up primordial dwarfism.
·
Primordial dwarfism can be difficult to
diagnose. This is because the small size and low body weight could be a sign of
other things, such as poor nutrition or a metabolic disorder.
To get more detailed
insight on Primordial Dwarfism Market Report @Request for a Sample Report here:
https://www.delveinsight.com/report-store/primordial-dwarfism-market
Some of Primordial Dwarfism Companies are:
·
GeneScience Pharmaceuticals
·
Merck
·
Genentech, Inc.
·
Pfizer
·
Novo Nordisk
·
EMD Serono
·
And Many Others
Primordial Dwarfism Therapies are:
·
Jintrolong® low
dose group
·
Recombinant
human growth hormone (r-hGH)
·
Somatropin
·
And Many Others
To get more detailed insight
about Primordial Dwarfism Therapies @Request for a Sample Report here: https://www.delveinsight.com/report-store/primordial-dwarfism-market
Sialidosis Market
Sialidosis is characterized by a
deficiency of the digestive enzyme, alpha-neuraminidase. The lack of this
enzyme results in an abnormal accumulation of complex carbohydrates known as
mucopolysaccharides, and of fatty substances known as mucolipids. Both of these
substances accumulate in bodily tissues. There are four types of Sialidosis:
Each type of Sialidosis is characterized by the age of onset and by the type of
physical and mental manifestations of this disorder.
Some of Sialidosis facts:
·
As per ISMRD, Sialidosis is among the rarest Lysosomal
Storage Diseases, affecting perhaps less than 1:4,000,000 worldwide and is
thought to be more common in people with Italian ancestry.
·
As per the International Advocate for
Glycoprotein Storage Diseases (ISMRD), Type I is the mildest form of Sialidosis,
with a range of onset from anywhere between 8-25 years of age.
·
According to NORD, Sialidosis affects males and
females in equal number.
·
The prevalence is estimated to be less than
1/1,000,000.
View Report: https://www.delveinsight.com/report-store/sialidosis-market
Get in touch with our Business executive for Rich and
Deep Healthcare
Consulting Solutions
DelveInsight’s Competitive
Intelligence Service includes a multidimensional coverage, helping to
keep track of competitors and gain traction in the dynamic market by overcoming
the challenges and expediting business growth through a strategic and tactical
approach.
Some of Newly Launched Report:
- Acute
Lung Injury Market
- Adamantinoma
Market
- Defibrillators
Market
- Urolithiasis
Market
- Cardiac
Resynchronization Therapy Device Market
- Aesthetic
Implants Market
- Alzheimer
Disease Market
- Central
Venous Catheters Market
- Biochips
Market
- Alopecia
Market
- Cardiac
Monitoring Devices Market
- Biliary
Tumor Market
- Foot
And Ankle Devices Market
- Hyperuricemia
Market
- Invasive
Candidiasis Market
- Global
Electrophysiology Devices Market
- Neurovascular
Devices Market
- Blood
Glucose Monitoring Systems Market
- Neurostimulation
Devices Market
- Human
Papilomavirus Market
- Capnography
Device Market
- Ventilator
Market
- Breast
Pumps Market
- Metastatic
Bone Pain Market
- Brain
Aneurysm Stents Market
- Atypical
Hemolytic Uremic Syndrome Ahus Market
- 2
Deletion Syndrome Market
- X
Linked Hypophosphatemia Market
- Parkinsons
Disease Related Dementia Market
- Ocular
Motility Disturbance Market
- Palmar
Hyperhidrosis Market Size
- Pulse
Oximeters Market
- Diagnostic
Imaging Equipment Market
- Continuous
Renal Replacement Therapy Machines Market
- Pain
Management Devices Market
- Glycogen
Storage Disease Market
- Rituximab
Biosimilars Insight
- Epithelial
Ovarian Cancer Market
- Cardiac
Biomarkers Testing Devices Market
- Chronic
Myelogenous Leukemia Market
- Bone
Grafts And Substitutes Market
- Idiopathic
Membranous Nephropathy Market
- Advanced
Renal Cell Carcinoma Market
- Sialidosis
Market
- Prosthetic
Joint Infection Market
- Microsatellite
Stable Colorectal Cancer Market
- Higher-Risk
Chronic Myelomonocytic Leukemia Market
- Chondrosarcoma
Market
- Car
T Therapy For Acute Lymphoblastic Leukemia All Market
Related Blogs:
- Most
Promising Applications of Artificial
Intelligence (AI) in Healthcare Segment
- Mapping
the Biggest
Pharmaceutical Companies by Continents
- Widespread
Usage of HPV
Vaccine Reduces Cervical Cancers and Precancers
- Major
Drugs Decisions for Cardiovascular Diseases to Watch Through 2022
- Assessment
of Key Products that Got FDA Approval in Second Half (H2) of 2021
- Evaluation
of Rapidly Evolving Parkinson’s Disease Therapeutic Market
- Cybersecurity
in Healthcare: Major Threats and Challenges
- Top
Drugs To Watch in HIV (2025)
About Delveinsight:
DelveInsight Business Research is a leading Market Research, and
Business Consultant focused purely on Healthcare. It helps pharma companies by
providing them with end-to-end services to solve their business problems.
Get hold of all the Pharma and healthcare market research
reports on our market research subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
Connect With Us at:
Comments
Post a Comment